Butterfly Network, Inc. Q2 2026 Earnings Call Summary
Butterfly Network, Inc. reported Q2 2026 progress driven by POCUS, Home and Community Care, and Embedded partnerships. Embedded revenue rose 439% on the Midjourney partnership. Gross margin was 71%. Full-year 2026 revenue guidance was raised to $119 million-$123 million. Home and Community Care first commercial implementation starts Oct 1, with revenue in Q4 2026.
How this was made
The 30-second read
Why it matters
The most tradable elements are the raised FY 2026 revenue guidance and the dated roadmap for next-gen probe launch, Home and Community Care first commercial implementation, and US government readiness via VA authorization and expected FedRAMP certification.
Market read
Investors get a clearer revenue ramp narrative (guidance raise and milestone dates) alongside near-term margin and regional headwinds (ASP down, international revenue down).
What to watch
FedRAMP timing (Q3) and Home and Community Care revenue materialization (Q4 2026) are execution-dependent; any slippage could compress the implied revenue ramp despite the raised full-year range.
Background
This is a Q2 2026 earnings call summary for Butterfly Network, focused on growth engines (POCUS, Home and Community Care, Embedded partnerships) and commercialization/regulatory milestones.
Ticker impact
Butterfly Network raised full-year 2026 revenue guidance to $119M-$123M and outlined Q1 2027 next-gen probe launch timing.
Near-term bias higher on guidance and milestone clarity; volatility likely around margin/ASP and international weakness details.
The article provides multiple new, decision-relevant datapoints tied to Butterfly’s revenue trajectory and regulatory/commercial timing, which typically drive earnings-call repricing. Offsetting negatives (ASP down 12%, international revenue -14%) temper conviction.
Market effects
Could strengthen sentiment toward ultrasound/POCUS commercialization models that combine hardware with enterprise software and partner-driven embedded revenue.
US government channel expansion via VA authorization and expected FedRAMP certification may increase demand expectations for US-focused medtech buyers.
International revenue decline (-14%) highlights uneven adoption outside the US, which may affect how investors underwrite global growth rates.
Counterpoint
The guidance raise may rely on future partner commercialization and chip-delivery timing, while current quarter economics show ASP pressure and international weakness.
Key entities
- companyButterfly Network, Inc.
Medical ultrasound company discussing Q2 performance drivers, raised FY 2026 guidance, and upcoming product and commercialization milestones.
- partnershipMidjourney partnership
Embedded business driver cited for a 439% revenue increase and future Apollo chip deliveries scheduled for late 2027 or early 2028.
- partnershipVCOM partnership
Included preferred pricing for legacy iQ+ inventory, leading to a 12% decrease in ASP for the quarter.
